Search | TVST | ARVO Journals

Showing 1 – 20 of 145

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina October 2024

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

PDF

Maureen G. Maguire; David G. Birch; Jacque L. Duncan; Allison R. Ayala; Lauren N. Ayton; Janet K. Cheetham; Peiyao Cheng; Todd A. Durham; Frederick L. Ferris, III; Carel B. Hoyng; Rachel M. Huckfeldt; Glenn J. Jaffe; Christine Kay; Eleonora M. Lad; Bart P. Leroy; Wendi Liang; Lee S. McDaniel; Michele Melia; Michel Michaelides; Mark E. Pennesi; José-Alain Sahel; Lassana Samarakoon; on behalf of the REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: cohort studies, eye, natural history, outcome measures, retinal degeneration, sample size, surrogate endpoints, vision, united states food and drug administration, perimetry
Trans. Vis. Sci. Tech.. 2024; 13(10):15. https://doi.org/10.1167/tvst.13.10.15

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Greggory Gahn; Peter K Kaiser; Arshad M. Khanani; Carl J Danzig; Jeffrey S Heier; Julie Clark; Liansheng Zhu; Hersh Patel; Don Luo; Nikhil Patel; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4400.

ARVO Annual Meeting Abstract June 2024

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

Todd Schneiderman; Victor H Gonzalez; David S Boyer; Richard B Rosen; Samantha Xavier; Allen Hu; David Warrow; Eleonora M Lad; Diana V Do; Allen Ho; Glenn J Jaffe; Marion Ronit Munk; Cindy Croissant; Stephanie Tedford; Rene Ruckert; Clark Tedford

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):379.

ARVO Annual Meeting Abstract June 2023

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Jennifer I Lim; Shih-Jen Chen; Nathan Steinle; Glenn J Jaffe; Bianca S Gerendas; Francis Abreu; Acner Camino; Kara Gibson; Nitin Jain; Eugene Shildkrot; Audrey Souverain; Yannan Tang; Jeffrey Willis; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2815.

ARVO Annual Meeting Abstract June 2023

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Carl J Danzig; Peter Kaiser; David Lally; Glenn J Jaffe; Arshad M. Khanani; Charles Clifton Wykoff; Jeffrey S Heier; Justin Tang; Liansheng Zhu; Julie Clark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):984.

ARVO Annual Meeting Abstract June 2023

Multimodal Identification and Quantification of Subretinal Fibrosis in Eyes with Neovascular AMD in CATT

Grace E Nipp; Sandra S Stinnett; Stephanie J Chiu; Gui-Shuang Ying; Ebenezer Daniel; Maureen G Maguire; Dilraj Singh Grewal; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2384.

ARVO Annual Meeting Abstract June 2023

Reproducibility of ellipsoid zone (EZ) parameters measured under different OCT scan settings in retinitis pigmentosa (RP)

Xiangrong Kong; Kevin Choy; Muhammad Khan; Yuchen Lu; Dagmar Wehling; Peter A Campochiaro; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4659.

ARVO Annual Meeting Abstract June 2023

Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration

Arshad M. Khanani; Vrinda S Hershberger; Christine Nichols Kay; Allen Hu; David Aaron Eichenbaum; Glenn J Jaffe; Carol Chung; Somayeh Honarmand; Chyong Nien; Schonmei Lee; Harsha Kabra; David Kirn; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5055.

ARVO Annual Meeting Abstract June 2023

LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Marion Ronit Munk; Victor Gonzalez; David S Boyer; Richard B Rosen; Samantha Xavier; Allen Hu; David Warrow; Eleonora M.Lad; Diana V Do; Todd Schneiderman; Allen Ho; Glenn J Jaffe; Stephanie Tedford; Cindy Croissant; Rene Ruckert; Clark Tedford

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5059.

ARVO Annual Meeting Abstract June 2022

Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells

Ping Yang; Rose Trimpey-Warhaftig; Jin Mo Koo; John Park; Hampar Karageozian; Vicken H Karageozian; Zixuan Shao; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3041 – F0412.

ARVO Annual Meeting Abstract June 2022

The novel secretome ST266 promotes survival of oxidant-stressed human RPE by a mechanism involving the Akt/mTOR/p70S6k/GSK-3b pathway

Rose Trimpey-Warhaftig; Nicholas Besley; Scott Lallier; Ping Yang; Howard Wessel; Larry Brown; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):776 – F0335.

ARVO Annual Meeting Abstract June 2022

Autonomous Robotically Aligned OCT Enables Remote, Telehealth Retinal Imaging and Angiography

Ryan P McNabb; Ailin Song; Kyung-Min Roh; Pablo Ortiz; Mark Draelos; Stefanie Schuman; Glenn J Jaffe; Joseph A. Izatt; Anthony N Kuo

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4453 – F0132.

ARVO Annual Meeting Abstract June 2022

Comparison of Quantitative Retinal and Choroidal Measurements in Eyes with Neovascular Age Related Macular Degeneration Using Fully Automatic Software Versus Native Spectralis Software

Stanley Saju; Stephanie J Chiu; Glenn Jaffe; Dilraj S Grewal

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1037 – F0284.

ARVO Annual Meeting Abstract June 2022

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Marion Ronit Munk; Victor H. Gonzalez; David S Boyer; Diana V Do; Samantha Xavier; Allen Hu; Richard B Rosen; Eleonora Lad; Todd Schneiderman; Allen C Ho; Glenn Jaffe; David Warrow; Stephanie Tedford; Cindy Croissant; Rene Ruckert; clark tedford

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):379 – F0210.

ARVO Annual Meeting Abstract June 2022

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Caroline R Baumal; John Kitchens; Glenn Jaffe; Bianca S Gerendas; Francis Abreu; Kemal Asik; Acner Camino; Nitin Jain; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3851.

Clinical Trials December 2021

Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments

PDF

Jennifer K. Sun; Kristin Josic; Michele Melia; Adam R. Glassman; Clare Bailey; Kakarla V. Chalam; Emily Y. Chew; Catherine Cukras; Sandeep Grover; Glenn J. Jaffe; Richard Lee; Jared S. Nielsen; Darby J. S. Thompson; Henry E. Wiley; Frederick L. Ferris, 3rd; for the DRCR Retina Network
TAGS: diabetic macular edema, eye, optical coherence tomography, sensitivity analysis
Trans. Vis. Sci. Tech.. 2021; 10(14):34. https://doi.org/10.1167/tvst.10.14.34

Includes: Supplemental Content

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

A multimodal deep learning (DL) model to predict visual acuity response in the CATT study

Jelena Novosel; Neha Anegondi; Jian Dai; Ebenezer Daniel; Glenn J Jaffe; Maureen G Maguire; Jeffrey R Willis

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):81.

ARVO Annual Meeting Abstract June 2021

Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells

Ping Yang; Nicholas Anthony Besley; Scott W Lallier; Zixuan Shao; John Y Park; Hampar Karageozian; Vicken Karageozian; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2697.

ARVO Annual Meeting Abstract June 2021

Reduction in Cystoid Macular Edema and Ellipsoid Zone Reconstitution in Non-paraneoplastic Autoimmune Retinopathy Treated with Anti-Interleukin-6 Monoclonal Antibodies

Jordan Deaner; Glenn J Jaffe; Robert T Keenan; Lisa Carnago; Dilraj Grewal

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1406.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Multimodal Identification and Quantification of Subretinal Fibrosis in Eyes with Neovascular AMD in CATT

Reproducibility of ellipsoid zone (EZ) parameters measured under different OCT scan settings in retinitis pigmentosa (RP)

Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration

LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells

The novel secretome ST266 promotes survival of oxidant-stressed human RPE by a mechanism involving the Akt/mTOR/p70S6k/GSK-3b pathway

Autonomous Robotically Aligned OCT Enables Remote, Telehealth Retinal Imaging and Angiography

Comparison of Quantitative Retinal and Choroidal Measurements in Eyes with Neovascular Age Related Macular Degeneration Using Fully Automatic Software Versus Native Spectralis Software

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

A multimodal deep learning (DL) model to predict visual acuity response in the CATT study

Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells

Reduction in Cystoid Macular Edema and Ellipsoid Zone Reconstitution in Non-paraneoplastic Autoimmune Retinopathy Treated with Anti-Interleukin-6 Monoclonal Antibodies

To View More...

You must be signed into an individual account to use this feature.